ProfileGDS5678 / 1434220_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 75% 73% 78% 74% 74% 76% 75% 75% 76% 75% 75% 75% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0013876
GSM967853U87-EV human glioblastoma xenograft - Control 24.9908275
GSM967854U87-EV human glioblastoma xenograft - Control 34.7225573
GSM967855U87-EV human glioblastoma xenograft - Control 45.5803178
GSM967856U87-EV human glioblastoma xenograft - Control 54.8710774
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7918474
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9869576
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.0234575
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9707175
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1688376
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.973675
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9740875
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8972375
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9940475